Amphastar Pharmaceuticals (AMPH) PT Raised to $18 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Amphastar Pharmaceuticals (AMPH) PT Raised to $19 at Piper Jaffray
March 25, 2015 6:58 AM EDTPiper Jaffray analyst David Amsellem reiterated an Overweight-rating and boosted his price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $19.00 (from $16.00) following solid execution in Q4.
Amsellem commented, "Amphastar reported a 4Q14 net loss per share of ($0.03) on revenues of $56M, compared to the Street estimates of ($0.07) and... More
Amphastar Pharma (AMPH) Tops Q4 EPS by 7c
March 24, 2015 4:03 PM EDTAmphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of ($0.03), $0.07 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $55.9 million, versus $54.9 million reported last year.
For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.
... More